Core One Labs Inc. (COOL) | Finanzwire

Basculer en Français

8296	Companies
114902	Keywords
55328	Articles
62458	Press releases

Home
Companies
Core One Labs Inc.

BRIEF

published on 07/09/2024 at 01:20, 4 months 12 days ago

Core One Labs Enters into Loan Agreement with Right Season Investments

Loan Agreement Psychedelic Medicines Core One Labs Right Season Investments Psilocybin Production
PRESS RELEASE

published on 07/09/2024 at 01:15, 4 months 12 days ago

Core One Enters into Loan Agreement with Right Season Investments
Core One Labs Inc. secures CDN$300,000 loan from Right Season Investments Corp. for working capital. Company focuses on developing psychedelic medicines and innovative delivery systems

Loan Agreement Working Capital Core One Labs Inc. Psychedelic Medicines Biotechnology Research
PRESS RELEASE

published on 12/09/2023 at 00:55, 11 months 12 days ago

Core One Labs Inc. Announces Initial Agreement for Potential Sale of Proprietary Biosynthetic Psilocybin, Facilitating Entry into the International Market
PRESS RELEASE

published on 12/02/2023 at 01:00, 11 months 19 days ago

Core One Labs’ Akome Reveals Impressive Results for its Psychedelic Bio-Compounds Designed to Target Alzheimer’s and Parkinson’s, Showing Potential to Outperform Current Treatment Methods
Core One Labs Inc. ('Core One') shares exciting results of Stage 2 animal model studies on Akome's five plant bioactives and DMT, demonstrating potential to outperform current treatment methods for Alzheimer's and Parkinson's. Research team to investigate elevated concentration levels of Bio-Compounds in further studies

Core One Labs Inc. Akome Stage 2 Animal Model Studies Bio-compounds Alzheimer's And Parkinson's
PRESS RELEASE

published on 08/05/2023 at 01:25, 1 year 3 months ago

Core One's Akome Reveals Groundbreaking Positive Results from its Second Round of Stage 1 Animal Model Studies for Bio-Compounds Targeting Alzheimer’s and Parkinson's Disease
PRESS RELEASE

published on 08/02/2023 at 01:55, 1 year 3 months ago

Core One Labs', Awakened Biosciences, Announces Groundbreaking Step Forward in Isolating and Purifying Psilocybin from Mushroom Biomass
PRESS RELEASE

published on 07/29/2023 at 01:25, 1 year 3 months ago

Core One's Akome Receives Positive Preliminary Stage 1 Animal Model Study Results for Bio-Compound Targeting Alzheimer’s and Parkinson’s Disease
PRESS RELEASE

published on 07/22/2023 at 00:55, 1 year 3 months ago

Core One Labs Enters into Letter of Intent for First Sale of Its Psychedelic Compounds
PRESS RELEASE

published on 07/12/2023 at 01:25, 1 year 4 months ago

Core One's Vocan Biotechnologies Incorporates New Bioreactor Equipment into Production Process Significantly Increasing Throughput of Proprietary Biosynthetic Psilocybin
PRESS RELEASE

published on 07/07/2023 at 23:55, 1 year 4 months ago

Core One's Vocan Files International Patent for its Breakthrough Proprietary Biosynthetic Psilocybin Production Method

Accesswire

Published on 11/21/2024 at 13:00, 29 minutes ago

Aclara Secures Funding from Corfo's Innovation High-Tech Program for Artificial Intelligence Project
Published on 11/21/2024 at 13:00, 29 minutes ago

Telomir Pharmaceuticals Confirms Age Reversal, Increased Longevity and Improved Healthspan in Groundbreaking Preclinical Study with Telomir-1
Published on 11/21/2024 at 13:00, 29 minutes ago

Toggle3D.ai Rebrands as FOTOgpt.ai to Usher in a New Age of AI-Powered Photography
Published on 11/21/2024 at 13:00, 29 minutes ago

Nextech3D.ai Spin-Out Rebrands as FOTOgpt.ai to Usher in a New Era of AI-Powered Photography
Published on 11/21/2024 at 13:00, 29 minutes ago

Clean Air Metals Announces Positive Results from Innovative Seismic Survey at the Escape Deposit Down-Plunge Extension

View all ACCESSWIRE

EQS Group

Published on 11/21/2024 at 13:15, 14 minutes ago

NOTICE OF ANNUAL GENERAL MEETING
Published on 11/21/2024 at 12:35, 54 minutes ago

audius with successful third quarter 2024 - total revenue grows by +9.2% and EBITDA by +14.6
Published on 11/21/2024 at 12:15, 1 hour 14 minutes ago

Hardman & Co Investor Forum Research on Shield Therapeutics (STX): Proactive cash management to cashflow-breakeven
Published on 11/21/2024 at 12:06, 1 hour 22 minutes ago

IVU AG publishes Quarterly Report Q3-2024
Published on 11/21/2024 at 12:00, 1 hour 29 minutes ago

Holding(s) in Company

Les Echos

Published on 11/21/2024 at 06:58, 6 hours 31 minutes ago

Net Asset Value per share increases with 9.4% in six months to EUR 55.6 thanks to continued strong growth performance of the portfolio
Published on 11/20/2024 at 19:20, 18 hours 9 minutes ago

Peugeot Invest Board of Directors to evolve following the May 2025 Annual General Meeting
Published on 11/20/2024 at 17:45, 19 hours 44 minutes ago

MEDESIS PHARMA HAS COMPLETED ITS CLINICAL STUDY FOR THE TREATMENT OF ALZHEIMER'S DISEASE WITH NANOLITHIUM
Published on 11/20/2024 at 17:45, 19 hours 44 minutes ago

Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2024
Published on 11/20/2024 at 07:45, 1 day 5 hours ago

Gimv sells to Fremman Capital a majority stake in outpatient rehabilitation specialist rehaneo

View all LES ECHOS COMFI WIRE